Introducere. Una dintre problemele importante ale tratamentului in gonoree este reprezentata de capacitatea deosebita aN. Gonorrhea de a dezvolta rapid rezistenta fata de antibioticele utilizate. Scopul studiului de fata este de a aprecia eficacitatea lomefloxacinei in tratamentul gonoreei acute necomplicate.

Material si metoda. Studiul a fost efectuat pe un lot de 60 de bolnavi ce gonoree acuta necomplicata (uretrita si respectiv cervivita) diagnosticati la Centrul Dermato-venerologic Bucuresti. Diagnosticul a fost stabilit prin examen direct pe frotiu si cultura. Bolnavilor li s-a administrat cate 400 de mg PO de lomefloxacina in doza unica.

Rezultate. Varsta bolnavilor cuprinsi in studiu, 37 de barbati si 23 de femei, a fost cuprinsa intre 17 si 45 de ani (varsta medie de 23,4 ani). Simptomatologia s-a remis in toate cazurile, iar controalele clinic si bacteriologic la 1, 3 si 7 zile au fost negative in toate cazurile. Nu au fost observate reactii adverse.

Concluzii. Lomefloxacina, o noua fluorochinolona de generatia a treia, reprezinta o alternativa eficienta pentru tratamentul gonoreei acute necomplicate.

Background. One of the most important problems of the treatment of gonorrhea is the great capacity of Neisseria gonorrheae to develop resistance against antimicrobial agents. The aim of this study was to evaluate the effectiveness of lomefloxacin in the treatment of acute uncomplicated gonorrhea.

Methods. The study was performed among 60 patients who attended Dermato-venereological Center Bucharest for acute uncomplicated gonorrhea. The diagnosis was based upon identification of N. gonorrhea by Gram-stained smear and culture. The patients were treated with a single dose of 400 mg lomefloxacin administrated PO.

Results. The patients, 37 men and 23 women,were age from 17 to 45 years (mean age 23.4 years). Symptomatology disappeared and posttherapeutic controls (clinical and laboratory) at 1, 3 and 7 days were negative in all cases. No adverse reactions were observed.

Conclusions. Lomefloxacin, a new fluoroquinolone of the third generation, has proven to be an efficient, well tolerated alternative for the treatment of acute uncomplicated gonorrhea.